Led by a 5 strong clinical operations team from Aptus Clinical, the AZD5363 ‘BEECH’ study recently completed recruitment with a total of 110 patients randomised to this Phase 2b study examining the safety, tolerability and efficacy of AZD5363 when combined with Paclitaxel in Breast Cancer patients which is being conducted in 11 counties around the world.
15th January 2015
We are pleased to announce that we have entered into an agreement with OBI Pharma to support their physicians and scientists in the design of a translational medicine study to support the development of their breast cancer vaccine OBI-822.
14th June 2015
Steve McConchie, Aptus Clinical CEO, will be at Bio 2015 in Philadelphia from the 15th to the 18th of June at the Pennsylvania Convention Centre. We would be delighted to meet up with new or existing customers at the meeting. Please get in touch via the conference partnering system or leave a message via the Contact Us page. We hope to see you there.
8th May 2015
Steve McConchie, CEO and Jonathan Lewis, BDD will be attending the BioTrinity meeting in London on the 12th and 13th May 2015. We would be happy to meet with potential customers or partners at the meeting. Please send us a request via the partnering 360 website or send a text to our mobile phones at the numbers given on the contact us page. We look forward to hearing from you.
29th April 2015
"We are pleased to announce that Aptus Clinical has signed an agreement with United States based CTD Holdings Inc, (click here for press release). We are delighted to be collaborating with CTD Holdings and their other partners in this important programme. As our first agreement with a Company not located in the UK this is a significant milestone in the development of Aptus and further validates the value of our flexible clinical solutions to the global biotechnology sector”
6 April 2015
Our revamped website highlights our passion for Clinical Development and provides information for clients and clinical research professionals on our full range of services and working with us.
Aptus Clinical is pleased to announce that it is providing Study Management, Data Management and Analysis & Reporting services to AstraZeneca on the ground breaking Me&My COPD mHealth study as part of AZs Intelligent Pharmaceuticals programme. The provision of these highly experienced clinical staff in the respiratory arena is a further build on the therapeutic area competence offered by Aptus Clinical.
We are pleased to announce that we have signed a Professional Service Agreement with AstraZeneca. We are delighted to be partnering with AstraZeneca and are looking forward to working with them on the BEECH study. This is a significant milestone in the development of our Company and great indicator of the value we can bring to client's drug projects through the highly experienced team of clinical research experts that we are building.